Replies to post #3028 on Tao Synergies Inc (TAOX)

[F1ash]

Would you take a drug that is "safe to a large degree", but may cause long term side effects unless you were desperate and had little quality of life left?

There was no possibility the 2-73 patients were "depressed". It was a 3rd party trial paid for and overseen by the Aussie government."



So did they have so little confidence in their drug that they were only willing to test it on someone else's dime?

On depression vs Alzheimer's:



"Similar symptoms

Some of the symptoms common to both Alzheimer's and depression include:

Loss of interest in once-enjoyable activities and hobbies

Social withdrawal

Memory problems

Sleeping too much or too little

Impaired concentration

With so much overlap in symptoms, it can be hard to tell the difference between the two disorders, especially since they often occur together. A thorough physical exam and psychological evaluation can be helpful in making a diagnosis.

But, many people with more advanced Alzheimer's disease may not be able to express how they feel."

"Early Alzheimer's disease and depression share many symptoms, so it can be hard — even for doctors — to distinguish between the disorders. Plus, many people with Alzheimer's disease also are depressed."

http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048362

What is the primary outcome measure in Anavex's current trial? Post it here when you find it.

[Whatsupp]

"How can you prove safety and dosage with a hand full of people?"

That's why bryostatin is so far ahead of 2-73, only a handful of patients have taken 2-73, hundreds have taken bryoststin.

[doingmybest]

XenaLives, I am perplexed by your positions here. While I cannot go along with the most positive expectations from this board, I am puzzled how you seem to write off the possibility of success here, if that is your position. When I weigh the development work and available data from both the AVXL drug and the NTRP drug I lean toward the AVXL drug having a little more efficacy data to work with but both are so early I am not sure how anyone can draw any real conclusions. I am optimistic on both drugs with little to g on with both drugs. A 32 patient open label trial in Australia with mild to moderate patients is a start but barely a start. A 9 patient P2a is not even a start yet. The entire body of science shows potential for both. I have seen drugs pop up from unexpected situations out of the ashes of other attempted or approved indications and I am hoping it happens again with bryostatin. I am thrilled one will publish significant high value development data shortly to see if the hopes of many will flourish or be dashed. I am bullish on both drugs, theoretically liking the mechanism of action more with the AVXL drug a little more, though it appears to be a more subtle PD activity while being very intrigued by the NTRP company aggressive strategy to tackle severe patients displaying confidence and a more direct mechanism of action resulting from extensive years of focused research.

Are you playing the devil's advocate or just anti-bryostatin?